Buyer licensing framework

License a defined release.

The executed agreement should identify the supplier and buyer, exact release, approved tasks, data categories, source restrictions, geography and permitted users. This outline grants no licence to participant data.

Training, fine-tuning, evaluation, publication and onward access are separate uses to resolve explicitly. A broad AI use label is not a substitute for a defined scope.

Connect the licence to the source.

• Document authority to collect and provide the agreed data for the agreed uses.
• Define each party’s privacy role and any processing or transfer agreement required.
• Record restrictions for sensitive modalities, provider exports, derived data and third-party materials.
• Prohibit re-identification, unauthorized contact and uses outside the agreement.

Agree what counts as delivery.

Specify schema, population, coverage, source evidence, annotations, quality thresholds and correction handling. Set acceptance and remediation terms against measurable requirements.

Clinical review, if contracted, should identify the reviewers’ qualifications, task, rubric and adjudication process. It should not imply validation of every clinical interpretation or model output.

Cover what happens after delivery.

• Define access controls, permitted subprocessors, retention and deletion obligations.
• Set notification and cooperation duties for incidents, corrections and participant rights requests.
• Separate treatment of source records, annotations, derivatives, model weights and published results.
• Agree audit evidence, version tracking, renewal, termination and any permitted onward sharing.

Price the collection and the rights.

A pilot quote should separate study setup, recruitment and retention, collection costs, processing and expert review, and the scope of the licence. Volume, duration, modality and access rights affect the work. No standard per-record price or guaranteed cohort availability is asserted here.